Printer Friendly

MEDIMMUNE PROMOTES KISHBAUCH TO PRESIDENT & COO

 GAITHERSBURG, Md., May 24 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI) today announced that the board of directors have appointed Michael D. Kishbauch president and chief operating officer and have elected him to the board. Previously, Mr. Kishbauch was MedImmune's executive vice president. The position of chief operating officer is new to the company. Mr. Kishbauch succeeds Wayne Hockmeyer, Ph.D., as president. Dr. Hockmeyer is now MedImmune's chairman and chief executive officer.
 "Since joining us in December, Mike Kishbauch has been an invaluable member of our MedImmune team," said Dr. Hockmeyer. "His experience in marketing and product management has been and will be a great asset to MedImmune as we move toward our goal of becoming a fully integrated biopharmaceutical company."
 "With an established sales force in place for our first product, CytoGam(R), and a Product License Application filed with the Food and Drug Administration for Respivir(TM), MedImmune's second product, this is an exciting time for the company and I am delighted to assume the title of president and chief operating officer," said Mr. Kishbauch.
 Mr. Kishbauch joined MedImmune in December 1992 as executive vice president. Previously, Mr. Kishbauch spent 10 years at CIBA-Geigy holding several senior positions in planning, marketing and product management. At CIBA-GEIGY he successfully launched Habitrol(TM), a smoking cessation patch, and Volatren(TM), an anti-arthritic. Mr. Kishbauch also helped to formulate the company's strategy to double its field sales force in two years from 750 to 1,500 representatives. Prior to joining CIBA-GEIGY, Mr. Kishbauch spent six years in brand management at Proctor & Gamble Company. Mr. Kishbauch holds an M.B.A. from the Warton School of Business at the University of Pennsylvania and a bachelor of arts in biology from Wesleyan University.
 MedImmune, Inc. was formed in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of certain infectious diseases and cancers. MedImmune's corporate headquarters are in Gaithersburg.
 -0- 5/24/93
 /CONTACT: David M. Mott, vice president-business development and planning of MedImmune, 301-417-0770; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for MedImmune/
 (MEDI)


CO: MedImmune, Inc. ST: Maryland IN: MTC SU: PER

TS-WB -- NY062 -- 1716 05/24/93 12:38 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 24, 1993
Words:368
Previous Article:DIGIBOARD'S SERIAL PORT LINE FIRST TO SUPPORT WINDOWS NT; ENTIRE MULTIPORT BOARD FAMILY TO SUPPORT MICROSOFT'S PREMIER OPERATING SYSTEM
Next Article:HARNISCHFEGER INDUSTRIES, INC. REPORTS SECOND QUARTER
Topics:


Related Articles
MEDIMMUNE ANNOUNCES FILING OF REGISTRATION STATEMENT FOR 2.5 MILLION SHARES OF COMMON STOCK
MEDIMMUNE SIX MONTHS REVENUES $7.9 MILLION EARNINGS $0.3 MILLION
MEDIMMUNE DISCONTINUES NEGOTIATIONS TO ACQUIRE MELVILLE BIOLOGICS FROM THE NEW YORK BLOOD CENTER
MedImmune to Acquire Aviron in Exchange Offer Valued at $1.5 Billion.
MedImmune and Medarex Announce Collaboration to Develop and Commercialize Fully Human Antibodies for Autoimmune Diseases.
MedImmune Completes Cellective Acquisition.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters